Veterinary-specific breakpoints for ceftiofur applicable to canine Escherichia coli
Journal of Clinical Microbiology · 12.08.2026 · 64 (8)
DOI: 10.1128/jcm.00299-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 12.08.2026. Verfasst von Xukun Dang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Technology Innovation Center for Food Safety Surveillance and Detection (Hainan), Sanya Institute of China Agricultural University, Sanya, China. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, Escherichia coli Infections, Dog Diseases. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Program of the 2025 Talent Fund, Veterinary Teaching Hospital, China Agricultural University, Independent Research Projects of the National Key Laboratory of Veterinary.
Abstract (Originalsprache)
Ceftiofur is a third-generation cephalosporin approved for veterinary applications and is used to treat Escherichia coli infections in dogs, particularly urinary tract infections (UTIs), in countries including China. Despite this use, there are no approved breakpoints for interpretation of ceftiofur susceptibility testing results. This absence limits the guidance that veterinarians need to effectively prescribe ceftiofur in dogs. It also limits the analysis of data from resistance monitoring and surveillance programs. This study aimed to establish ceftiofur interpretive categories and breakpoints that can be used to assess antimicrobial susceptibility testing results for canine E. coli isolates. Our methods included a definition of the wild-type cutoff (CO WT ) based on resistance phenotypes from two sources, deriving the pharmacokinetics/pharmacodynamics (PK-PD) cutoff (CO PD ) through PK-PD analyses and Monte Carlo simulations and determining the clinical cutoff (CO CL ) from a trial in dogs. Minimal inhibitory concentration (MIC) data were collected from China and the European database (European Committee on Antimicrobial Susceptibility Testing [EUCAST]). CO WT was determined as 1 μg/mL. The CO PD was 0.25 μg/mL. Through a canine cystitis trial, a CO CL of 2 μg/mL was determined. Based on these findings and Clinical and Laboratory Standards Institute (CLSI)-recommended methods, we propose urinary tract infection-specific MIC breakpoints of ≤1 µg/mL (susceptible), 2 μg/mL (intermediate), and ≥4 µg/mL (resistant) and corresponding disk diffusion zone diameter breakpoints, determined by the error rate-bounded (ERB) method, of ≥23 mm (susceptible), 20–22 mm (intermediate), and ≤19 mm (resistant). The systemic breakpoints (non-urine) were determined to be ≤0.125 µg/mL (susceptible), 0.25 μg/mL (intermediate), and ≥0.5 µg/mL (resistant). IMPORTANCE Ceftiofur can be legally used, but laboratories and veterinarians lack canine-specific breakpoints to determine whether an isolate is susceptible or resistant. Without such criteria, test results can be inconsistent, treatment choices uncertain, and early signs of emerging resistance overlooked. This study fills that gap by defining evidence-based, canine-specific breakpoints for ceftiofur, particularly for urinary tract infections (UTIs). Adoption of these breakpoints will allow more consistent reporting by diagnostic laboratories, improve therapeutic decision-making for veterinarians, and provide a reliable basis for resistance surveillance. These advances strengthen the One-Health antimicrobial stewardship and help preserve the effectiveness of important antimicrobials for companion animals and the wider community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Technology Innovation Center for Food Safety Surveillance and Detection (Hainan), Sanya Institute of China Agricultural University, Sanya, China.
- State Key Laboratory of Veterinary Public Health Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- Veterinary Teaching Hospital, China Agricultural University, Beijing, China.
- Key laboratory of Animal Antimicrobial Resistance Surveillance, Ministry of Agriculture and Rural Affairs, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China.
ORCID-Profile: Xukun Dang, Fupin Hu, Congming Wu, Mark G Papich, Jianzhong Shen, Marilyn N Martinez, Stefan Schwarz, Zhaofei Xia, Yang Wang
Förderung
- General Program of the 2025 Talent Fund, Veterinary Teaching Hospital, China Agricultural University
- Independent Research Projects of the National Key Laboratory of Veterinary
Zitieren
APA
Dang, X., Chen, S., Lyu, H., Zou, Z., Sun, D., Yan, L., Wang, T., Huang, C., Li, Y., Ma, S., Bai, R., Jiang, J., Zhai, W., Wang, L., Hu, F., Wu, C., Papich, M. G., Shen, J., Martinez, M. N., …, & Wang, Y. (2026). Veterinary-specific breakpoints for ceftiofur applicable to canine Escherichia coli. Journal of Clinical Microbiology, 64(8). https://doi.org/10.1128/jcm.00299-26
Vancouver
Dang X, Chen S, Lyu H, Zou Z, Sun D, Yan L, et al. Veterinary-specific breakpoints for ceftiofur applicable to canine Escherichia coli. Journal of Clinical Microbiology. 2026;64(8). doi:10.1128/jcm.00299-26
BibTeX
@article{Dang2026,
author = {Dang, Xukun and Chen, Siyu and Lyu, Hening and Zou, Zhiyu and Sun, Da and Yan, Lin and Wang, Tongran and Huang, Chuangpeng and Li, Yifei and Ma, Shizhen and Bai, Rina and Jiang, Junyao and Zhai, Weishuai and Wang, Lu and Hu, Fupin and Wu, Congming and Papich, Mark G and Shen, Jianzhong and Martinez, Marilyn N and Schwarz, Stefan and Xia, Zhaofei and Wang, Yang},
title = {Veterinary-specific breakpoints for ceftiofur applicable to canine Escherichia coli},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {8},
doi = {10.1128/jcm.00299-26}
}
EUVIMED